{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:28:07Z","timestamp":1792096087216,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008710","name":"Dementia Australia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.arr.2025.102981","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:35:07Z","timestamp":1764866107000},"page":"102981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"114","author":[{"given":"Grace H.","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.H.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-8837","authenticated-orcid":false,"given":"Edwin C.K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2025.102981_bib1","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1007\/s10072-024-07477-w","article-title":"The efficacy and safety of lecanemab 10 mg\/kg biweekly compared to a placebo in patients with Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Abdelazim","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.arr.2025.102981_bib2","unstructured":"Alzheimer\u2019s Association, 2025a. Alzheimer\u2019s Network for Treatment and Diagnostics (ALZ-NET). \u3008https:\/\/www.alz-net.org\/\u3009 (accessed 13 August 2025)."},{"key":"10.1016\/j.arr.2025.102981_bib3","unstructured":"Alzheimer\u2019s Association, 2025b. What are the Causes and Risk Factors of Alzheimer's and Other Dementias? \u3008https:\/\/www.alz.org\/alzheimers-dementia\/what-is-alzheimers\/causes-and-risk-factors\u3009 (accessed 18 August 2025)."},{"key":"10.1016\/j.arr.2025.102981_bib4","article-title":"Unraveling Alzheimer\u2019s: the promise of aducanumab, lecanemab, and donanemab","volume":"60","author":"Ameen","year":"2024","journal-title":"Egypt. J. Neurol. Psychiat. Neurosurg."},{"key":"10.1016\/j.arr.2025.102981_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alz. Dement. Transl. Res. Clin. Inter."},{"key":"10.1016\/j.arr.2025.102981_bib6","article-title":"The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect","volume":"21","author":"Andrews","year":"2025","journal-title":"Alz. Dement"},{"key":"10.1016\/j.arr.2025.102981_bib7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","article-title":"Brain volume change following anti-amyloid; immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy","volume":"23","author":"Belder","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2025.102981_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2004.09.006","article-title":"Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate","volume":"44","author":"Buckner","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2025.102981_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neulet.2010.02.016","article-title":"Amyloid load in nondemented brains correlates with APOE e4","volume":"473","author":"Caselli","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2025.102981_bib10","article-title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","volume":"12","author":"Chen","year":"2025","journal-title":"J. Prev. Alzheimer's. Dis."},{"key":"10.1016\/j.arr.2025.102981_bib11","unstructured":"ClinicalTrials.gov, 2025. A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06566170?cond=Alzheimer%27s%20Disease&intr=Donanemab&page=1&rank=5\u3009 (accessed 15 August 2025)."},{"key":"10.1016\/j.arr.2025.102981_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer's disease","volume":"10","author":"Cohen","year":"2021","journal-title":"J. Prev. Alzheimer's. Dis."},{"key":"10.1016\/j.arr.2025.102981_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimer's. Dis."},{"key":"10.1016\/j.arr.2025.102981_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.arr.2025.102981_bib15","unstructured":"Deeks, J.J., Altman, D.G., McKenzie, J.E., Veroniki, A.A., 2024. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane. \u3008www.training.cochrane.org\/handbook\u3009."},{"key":"10.1016\/j.arr.2025.102981_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-022-01129-x","article-title":"Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer\u2019s disease","volume":"14","author":"Dhadda","year":"2022","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2025.102981_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2025.102981_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOE\u03b54 on A\u03b2 immunotherapy induced ARIA","volume":"16","author":"Foley","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2025.102981_bib19","author":"Grant","year":"2023","journal-title":"FDA Converts Nov. Alzheimer\u2019S. Dis. Treat. Tradit. Approv. U. S. Food Drugs Adm."},{"key":"10.1016\/j.arr.2025.102981_bib20","article-title":"Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease","volume":"9","author":"Gueorguieva","year":"2023","journal-title":"Alz. Dement. Transl. Res. Clin. Inter."},{"key":"10.1016\/j.arr.2025.102981_bib21","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alz. Dement. Transl. Res. Clin. Inter."},{"key":"10.1016\/j.arr.2025.102981_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimer\u2019S. Res. Ther."},{"key":"10.1016\/j.arr.2025.102981_bib23","article-title":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","volume":"12","author":"Hsu","year":"2025","journal-title":"J. Prev. Alz. Dis."},{"key":"10.1016\/j.arr.2025.102981_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3233\/JAD-210685","article-title":"Cognitive decline in Alzheimer's disease is not associated with APOE","volume":"84","author":"Katzourou","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2025.102981_bib25","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3390\/cells12212512","article-title":"Detrimental effects of ApoE \u03b54 on blood\u2013brain barrier integrity and their potential implications on the pathogenesis of Alzheimer\u2019s disease","volume":"12","author":"Kirchner","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.arr.2025.102981_bib26","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.3390\/jcm12165189","article-title":"Genetics of Alzheimer's disease in the African American population","volume":"12","author":"Logue","year":"2023","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.arr.2025.102981_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1346621","article-title":"A case for seeking sex-specific treatments in Alzheimer\u2019s disease","volume":"16","author":"Lynch","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2025.102981_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2025.102981_bib29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2025.102981_bib30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fnagi.2018.00312","article-title":"Inflammation: bridging age, menopause and APOE\u03b54 genotype to Alzheimer's disease","volume":"10","author":"Mishra","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2025.102981_bib31","first-page":"550","article-title":"Dementia and neurodegenerative diseases: what is known and what is promising at the cellular and molecular level","volume":"135","author":"Moroz","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.arr.2025.102981_bib32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/d41573-024-00116-1","article-title":"FDA approves third anti-amyloid antibody for Alzheimer disease","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2025.102981_bib33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2025.102981_bib34","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2025.102981_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-023-01681-z","article-title":"Association between APOE-\u03b54 allele and cognitive function is mediated by Alzheimer's disease pathology: a population-based autopsy study in an admixed sample","volume":"11","author":"Paradela","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.arr.2025.102981_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer's disease: treatment strategies and their limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2025.102981_bib37","first-page":"2083","article-title":"Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease","volume":"148","author":"Premkumar","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.arr.2025.102981_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/healthcare11010032","article-title":"Donanemab for Alzheimer\u2019s disease: a systematic review of clinical trials","volume":"11","author":"Rashad","year":"2022","journal-title":"Healthcare"},{"key":"10.1016\/j.arr.2025.102981_bib39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2025.102981_bib40","article-title":"TRAILBLAZER-ALZ 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease","volume":"21","author":"Salloway","year":"2025","journal-title":"Alz. Dement"},{"key":"10.1016\/j.arr.2025.102981_bib41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese patients with early Alzheimer\u2019s disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.arr.2025.102981_bib42","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment With Tau pathology and clinical outcomes","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2025.102981_bib43","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2025.102981_bib44","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2025.102981_bib45","article-title":"Effect of apolipoprotein E \u03b54 allele on the progression of cognitive decline in the early stage of Alzheimer's disease","volume":"6","author":"Suzuki","year":"2020","journal-title":"Alz. Dement. Transl. Res. Clin. Inter."},{"key":"10.1016\/j.arr.2025.102981_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer's. Res. Ther."},{"key":"10.1016\/j.arr.2025.102981_bib47","doi-asserted-by":"crossref","first-page":"586","DOI":"10.31128\/AJGP-05-18-4586","article-title":"Current approaches to the pharmacological treatment of Alzheimer\u2019s disease","volume":"47","author":"Tan","year":"2018","journal-title":"Aust. J. Gen. Pr."},{"key":"10.1016\/j.arr.2025.102981_bib48","article-title":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","volume":"12","author":"Wang","year":"2025","journal-title":"J. Prev. Alz. Dis."},{"key":"10.1016\/j.arr.2025.102981_bib49","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alz. Dement"},{"key":"10.1016\/j.arr.2025.102981_bib50","series-title":"Dementia","author":"World Health Organisation","year":"2025"},{"key":"10.1016\/j.arr.2025.102981_bib51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163725003277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163725003277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:49:31Z","timestamp":1773877771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163725003277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S1568163725003277"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2025.102981","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2025.102981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102981"}}